특허 및 논문

바이오솔빅스에 자료실을 확인해 보세요.
bt_bb_section_bottom_section_coverage_image

BIOSOLVIX ARCHIVE특허 및 논문

The use of aggregates of purified cardiomyocytes derived from human ESCs for functional engraftment after myocardial infarction

작성자
관리자
작성일
2024-01-31 16:26
조회
52

Moon SH, Kang SW, Park SJ, Bae D, Kim SJ, Lee HA, Kim KS, Hong KS, Kim JS, Do JT, Byun KH, Chung HM. The use of aggregates of purified cardiomyocytes derived from human ESCs for functional engraftment after myocardial infarction. Biomaterials. 2013 May34(16):4013-26.

 

Abstract

Embryonic stem cells (ESCs) have the capacity to undergo directed differentiation into contracting cardiomyocytes. Therefore, functional cardiomyocytes derived from human embryonic stem cells (hESC-CMs) are potential candidates for cellular cardiomyoplasty to regenerate the myocardium after infarction. However, the directed differentiation of hESCs induces not only contracting cardiomyocytes but also other cell types. Thus, a risk of teratoma formation and oncologic transformation exists following the transplantation of hESC-CMs containing other cell lineages. In addition, the transplantation of hESC-CMs into the infarcted myocardium limits therapeutic efficacy due to low viability and poor engraftment. In this study, we established an efficient preparation method to obtain pure contracting cardiomyocytes from hESCs. We also developed a delivery system to achieve enhanced viability and a functional connection with the host myocardium after transplantation in a myocardial infarction model. A serum-free medium was used to obtain pure contracting cardiomyocytes from other cell lineages after the cardiac differentiation of hESCs. Aggregates of purified hESC-CMs were formed, and then the expression of cardiomyocyte-specific markers and the viability of the aggregated CMs were examined in hypoxic conditions. In addition, we determined whether the viability of the hESC-CMs and their ability to engraft with the host myocardium could be enhanced by transplanting them as aggregates in a myocardial infarction model. The therapeutic efficacy of the cardiomyocytes was examined by immunohistochemical analyses as well as physiological analyses of left-ventricular function. We found that the transplantation of contracting hESC-CM aggregates improved their survival and function in infarcted rat hearts in comparison to the transplantation of dissociated cells. Our method using hESC-CMs can be considered an effective strategy for clinical applications without critical barriers.




전체 52
번호 제목 작성자 작성일 추천 조회
52
[특허] 콘케이브와 진탕배양 기법으로 형성된 전분화능 줄기세포 유래 신경세포 제조방법 및 이에 의해 제조된 3D 신경 오가노이드를 통한 약물 독성 평가방법
관리자 | 2024.02.22 | 추천 0 | 조회 40
관리자 2024.02.22 0 40
51
[특허] 중간엽줄기세포 패치 공배양 기법을 이용한 투명 배상체 유래 간세포 제조방법 및 이에 의해 제조된 3D 간 오가노이드를 통한 약물 독성 평가방법
관리자 | 2024.02.22 | 추천 0 | 조회 39
관리자 2024.02.22 0 39
50
[특허] 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
관리자 | 2024.02.22 | 추천 0 | 조회 37
관리자 2024.02.22 0 37
49
[특허] 인공 신경망을 이용한 심장 부정맥 유발약물의 스크리닝 방법
관리자 | 2024.02.20 | 추천 0 | 조회 44
관리자 2024.02.20 0 44
48
[특허] 3 차원 세포 배양용 미세유체칩 및 이를 이용한 3 차원 세포 배양방법
관리자 | 2024.02.20 | 추천 0 | 조회 44
관리자 2024.02.20 0 44
47
Translation reinitiating in c.453delC frameshift mutation of KCNH2 producing functional hERG K+ channels with mild dominant neg
관리자 | 2024.02.02 | 추천 0 | 조회 49
관리자 2024.02.02 0 49
46
Extracellular matrix cues regulate the differentiation of pluripotent stem cell-derived endothelial cells.
관리자 | 2024.02.02 | 추천 0 | 조회 52
관리자 2024.02.02 0 52
45
Ultraefficient extracellular vesicle–guided direct reprogramming of fibroblasts into functional cardiomyocytes.
관리자 | 2024.02.02 | 추천 0 | 조회 52
관리자 2024.02.02 0 52
44
In vitro maturation of human pluripotent stem cell-derived cardiomyocyte: A promising approach for cell therapy.
관리자 | 2024.02.02 | 추천 0 | 조회 63
관리자 2024.02.02 0 63
43
Enhancement strategy for effective vascular regeneration following myocardial infarction through a dual stem cell approach.
관리자 | 2024.02.02 | 추천 0 | 조회 59
관리자 2024.02.02 0 59